NCT02511028View on ClinicalTrials.gov

In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 27, 2015

Primary Completion Date

August 1, 2018

Study Completion Date

January 29, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Ferumoxytol

510mg (17mL) IV

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

National Institutes of Health Clinical Center (CC)

NIH

lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT02511028 - In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter